Healthcare Resource Utilization (HCRU) and Costs Among Previously-Treated Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Retrospective Analysis of SEER-Medicare Linked Claims
Speaker(s)
Rai P1, Paratane D2, Turkistani F2, Min J1, Rajagopalan K3, Hu X1
1Merck & Co., Inc., Rahway, NJ, USA, 2Anlitiks, Inc., Windermere, FL, USA, 3Anlitiks, Inc., WINDERMERE, FL, USA
Presentation Documents
OBJECTIVES: To describe HCRU and costs among previously-treated patients with mNSCLC.
METHODS: Retrospective analysis of ≥66-year-old patients with mNSCLC (stage IV) at diagnosis between 2007-2017 from the SEER data and Medicare linked claims through 2019 was conducted. Two cohorts were studied: (i) patients with non-squamous mNSCLC who initiated 2L/3L platinum-containing regimens (PCR) after receiving 1L/2L EGFR TKIs (Cohort 1), and (ii) patients (all histology) who initiated a subsequent line of therapy after receiving anti-PD(L)1 and chemotherapy concurrently or sequentially (Cohort 2). Index date was defined at therapy initiation. Per patient per month (PPPM) all-cause HCRU and costs were estimated as a total and by specific HCRU and cost type (i.e., NSCLC-related, AE-associated, other-cause) for different medical services (i.e., inpatient admission, outpatient, emergency, skilled-nursing), and pharmacy visits. Mean terminal-care costs were calculated as average of all costs incurred 30-days before death.
RESULTS: Mean age was 75.2±5.3 years, 33.3% males, and 61.8% whites in cohort 1 (N = 228) and 74.7±5.1 years, 48.4% males, and 81.3% whites in cohort 2 (N = 502). All-cause PPPM outpatient visits were higher than inpatient admission, skilled nursing, and emergency visits (Cohort 1 =2.03 vs 0.24, 0.03, 0.32, Cohort 2 =2.21 vs 0.24, 0.03, 0.47, respectively). Similarly, NSCLC-related PPPM outpatient visits were higher than inpatient admission, skilled nursing, and emergency visits (Cohort 1 =0.93 vs 0.23, 0.02, 0.20; Cohort 2 =0.93 vs 0.33, 0.03, 0.29, respectively). Total all-cause PPPM medical services costs were $9,612 (Cohort 1) and $10,200 (Cohort 2). Total AE-associated PPPM medical services costs in cohorts 1 and 2 were $5,309 and $6,951, respectively; driven by AE-associated inpatient admissions (Cohort 1=$3,170, Cohort 2 =$4,490). Mean terminal-care costs were $22,502 (Cohort 1) and $17,675 (Cohort 2), respectively.
CONCLUSIONS: Results from this study highlight the economic burden on previously-treated patients with mNSCLC.
Code
RWD145
Topic
Economic Evaluation, Epidemiology & Public Health, Study Approaches
Topic Subcategory
Public Health
Disease
Drugs, Oncology